Celltrion Initiates P-III Study of CT-P42 (biosimilar- aflibercept)
Shots:
- Celltrion has launched a global P-III clinical trial of CT-P42 which is an investigational biosimilar candidate referencing Regeneron’s Eylea (aflibercept)
- The study will enroll 300 patients with DME and aims to compare CT-P42’s efficacy- safety- pharmacokinetics- and immunogenicity against Eylea
- Celltrion adds CT-P42 to its pipeline of other investigational biosimilars- including CT-P17 (referencing Humira)- CT-P16 (referencing Avastin)- CT-P39 (referencing Xolair)- CT-P41 (referencing Prolia)- and CT-P43
Ref: Pulse | Image: Celltrion
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com